Date of Publication: 01-Feb-2026
INTELLIGENCE OVERVIEW
Agency: US FDA
The U.S. Food and Drug Administration (FDA) has launched the PreCheck Pilot Program, an initiative designed to modernize regulatory oversight of sterile pharmaceutical manufacturing by enabling enhanced communication and early issue identification between FDA and participating manufacturers checklist.
Industry Impact
The PreCheck program is expected to significantly impact sterile drug manufacturers by:
- Shifting oversight from periodic inspections to continuous regulatory engagement
- Enabling early detection of quality and compliance risks
- Supporting adoption of advanced manufacturing and quality management practices
- Potentially reducing inspection-related disruptions and compliance surprises
For the industry, PreCheck signals FDA’s move toward proactive, risk-based regulation, encouraging manufacturers to strengthen quality systems and embrace greater regulatory transparency.